1 / 51

Chapter 20 Tumor Immunology

Chapter 20 Tumor Immunology. Contents. Part Ⅰ Introduction Part Ⅱ Tumor antigens Part Ⅲ Immune response to tumors Part Ⅳ Mechanism of tumor escape from immune surveillance Part Ⅴ Immunotherapy of tumors. PartⅠ Introduction. Tumor immunology

ericlewis
Download Presentation

Chapter 20 Tumor Immunology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Chapter 20 Tumor Immunology

  2. Contents • PartⅠ Introduction • PartⅡ Tumor antigens • PartⅢ Immune response to tumors • PartⅣ Mechanism of tumor escape from immune surveillance • PartⅤ Immunotherapy of tumors

  3. PartⅠ Introduction • Tumor immunology tumor immunology is the study of ①the antigenic properties of tumor cells, ②the host immune response to these tumor cells, ③the immunological consequence of malignant cells growth to the host, ④and the means by which the immune system can be modulated to recognize tumor cells and promote tumor eradication. • Immunosurveillance

  4. PartⅡ Tumor antigens By their patterns of expression: • Tumor specific antigen (TSA) • Tumor associated antigens (TAA)

  5. Tumor specific antigen (TSA) Antigens that are only expressed on tumor cells but not on normal cells. high specificity. tumor-specific transplantation antigens (TSTA)

  6. tumor-specific transplantation antigens (TSTA) MCA(甲基胆蒽)

  7. Tumor associated antigens (TAA) Antigens that are also expressed on normal cells, but high expressed on tumor cells. Without tumor specificity: CEA, AFP

  8. Common tumor antigens • ①Embryonic antigens • ②Tumor antigens induced by virus • ③Mutated oncogene or suppressor oncogene encoded protein • ④Overexpressed cellular proteins

  9. ①Embryonic antigens • AFP (alpha fetoproein) • Normal<20 ng/ml • Hepatocarcinoma> 500ng/ml • CEA (carcinoembryonic antigen ) • Normal<20 ng/ml • colon carcinoma: 5-10 times higher

  10. Carcinoembryonic antigen:clinical application

  11. ②Tumor antigens encoded by genomes of oncogenic viruses: • HBV------ liver cancer • HPV------ cervical carcinoma • EBV------ B cell lymphoma and nasopharyngeal carcinoma

  12. Virus induced tumor antigen

  13. ③Products of mutated genes: • Some tumor antigens are produced by mutated oncogenes and tumor suppressor genes: Ras, p53

  14. ④Overexpressed cellular proteins and abnormally expressed proteins: • gp100, MAGE in melanomas • Cancer-testis antigens

  15. Part Ⅲ Immune response to tumors T cells: αβT, γδT NK cells • Cellular immunity Macrophages Dendritic cells • Humoral immunity

  16. (1)T lymphocytes: ①The principal mechanism of tumor immunity is killing of tumor cells by CTL Tumor antigens DC cross presentation CD8+T (CTL)

  17. ② CD4+T cells: secret cytokines

  18. ③γδT cells: -Not restricted by MHC - Kill cells that could escape from NK cells

  19. (2)NK cells: NK cells kill many types of tumor cells, especially cells that have reduced class I MHC expression and can escape killing by CTL.

  20. activated Tumor cell

  21. (3) Macrophages: ① APC ② release of lysosomal enzymes, reactive oxygen intermediates, nitric oxide ③ ADCC ④ secrete cytokines (4)Dendritic cells: ① APC------Induce adaptive immune response ② Inhibit tumor growth directly

  22. (5) Antibodies:① Activating complement ② ADCC③ Opsonization

  23. Antitumor Effect CMI NK cell Tumor cell Humoral Mechanisms Macrophage Kumar et al. Basic Pathology 6th ed. Figure 6-32

  24. PartⅣ Mechanism of tumor escape from immune surveillance ①Tumor antigens can’t elicit immune responses ------poor antigenicity and antigenic modulation. ②Tumor antigens may be sheltered or blocked. ③Class I MHC expression may be down-regulated on tumor cells so that they can not be recognized by CTL. ④Tumors may fail to induce CTL because most tumor cells do not express costimulators. ⑤Tumors secrete Immunosuppressive factors. ⑥Tumor cells induced apoptosis

  25. ①Tumor antigens can’t elicit immune responses ------poor antigenicity and antigenic modulation.

  26. ②Tumor antigens may be sheltered or blocked. The cancer cells that have the altered self-peptide are recognized and killed A mutation occurs that stops expression of the peptide and now the cells are no longer recognized.

  27. ③Class I MHC expression may be down-regulated on tumor cells so that they can not be recognized by CTL.

  28. ④Tumors may fail to induce CTL because most tumor cells do not express costimulators.

  29. ⑤Tumors secrete Immunosuppressive factors.

  30. ⑥Tumor cells induced apoptosis.

  31. Factors related to host: • Poor immune function • Tumor inhibit immune function of host

  32. PartⅤ Immunotherapy of tumors • Active immunotherapy • Target immunotherapy • Adoptive immunotherapy • Cytokine therapy • Gene therapy

  33. Active immunotherapy Stimulation of active host immune responses to tumors: • Vaccination with tumor cells , tumor antigens, or with APC.

  34. Target immunotherapy

  35. Adoptive immunotherapy • LAK (lymphokine activated killer) • TIL (tumor infiltrating lymphocyte) • CD3AK(CD3 antibody activated killer) • CTL (cytotoxic T lymphocyte)

  36. Cytokine therapy

  37. Gene therapy

More Related